

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/10, 39/116 // C07K 14/235		A1	(11) International Publication Number: WO 96/34623
			(43) International Publication Date: 7 November 1996 (07.11.96)
(21) International Application Number: PCT/CA96/00278		Andrew [CA/CA]; Apartment 414, 199 Upper Canada Drive, North York, Ontario M2P 1T3 (CA). BOUX, Leslie [CA/CA]; 128 Kirkland Boulevard, Kirkland, Quebec H9J 1P2 (CA). BARRETO, Luis [CA/CA]; 53 Crooked Stick Crescent, Concord, Ontario L4K 1P4 (CA). THIPPHA-WONG, John [CA/CA]; Apartment 602, 45 Carlton Street, Toronto, Ontario M5B 2H9 (CA). KLEIN, Michel, H. [CA/CA]; 16 Munro Boulevard, Willowdale, Ontario M2P 1B9 (CA). (74) Agent: STEWART, Michael, I.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA). (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 May 1996 (02.05.96)			
(30) Priority Data: 08/433,646 4 May 1995 (04.05.95) US 08/501,743 12 July 1995 (12.07.95) US			
(60) Parent Application or Grant (63) Related by Continuation US 08/501,743 (CIP) Filed on 12 July 1995 (12.07.95)			
(71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, North York, Ontario M2R 3T4 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): VOSE, John, R. [CA/FR]; 6, allée des Ecureuils, F-69160 Tassin-la-demi-lune (FR). FAHIM, Raafat, E., F. [CA/CA]; 524 Ceremonial Drive, Mississauga, Ontario L5R 2T2 (CA). JACKSON, Gail, E., D. [CA/CA]; 10 Annette Gate, Richmond Hill, Ontario L4C 5P3 (CA). TAN, Larry, U., L. [CA/CA]; 2424 Folkway Drive, Mississauga, Ontario L5L 3N3 (CA). HERBERT,			
Published With international search report.			
(54) Title: ACELLULAR PERTUSSIS VACCINES AND METHODS OF PREPARATION THEREOF			
(57) Abstract			
Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70 % of members of an at-risk population. The fimbrial agglutinogens may be prepared from a <i>Bordetella</i> strain, particularly a <i>B. pertussis</i> strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE OF INVENTIONACELLULAR PERTUSSIS VACCINES AND METHODS
OF PREPARATION THEREOFFIELD OF INVENTION

5 The present invention relates to acellular pertussis vaccines, components thereof, and their preparation.

REFERENCE TO RELATED APPLICATION

10 This application is a continuation-in-part of copending United States patent application no. 08/501,743 filed July 12, 1995, which itself is a continuation-in-part of copending United States patent application no. 08/433,646 filed May 4, 1995.

BACKGROUND TO THE INVENTION

15 Whooping cough or pertussis is a severe, highly contagious upper respiratory tract infection caused by *Bordetella pertussis*. The World Health Organization estimates that there are 60 million cases of pertussis per year and 0.5 to 1 million associated deaths (ref. 1. Throughout this specification, various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately following the claims. The disclosures of these references are hereby
20 incorporated by reference into the present disclosure). In unvaccinated populations, a pertussis incidence rate as high as 80% has been observed in children under 5 years old (ref. 2). Although pertussis is generally considered to be a childhood disease, there is increasing
25 evidence of clinical and asymptomatic disease in adolescents and adults (refs. 3, 4 and 5).
30

 The introduction of whole-cell vaccines composed of chemically- and heat-inactivated *B. pertussis* organisms in the 1940's was responsible for a dramatic reduction in

the incidence of whooping cough caused by *B. pertussis*. The efficacy rates for whole-cell vaccines have been estimated at up to 95% depending on case definition (ref. 6). While infection with *B. pertussis* confers life-long immunity, there is increasing evidence for waning protection after immunization with whole-cell vaccines (ref. 3). Several reports citing a relationship between whole-cell pertussis vaccination, reactogenicity and serious side-effects led to a decline in vaccine acceptance and consequent renewed epidemics (ref. 7). More recently defined component pertussis vaccines have been developed.

Antigens for Defined Pertussis Vaccines

Various acellular pertussis vaccines have been developed and include the *Bordetella pertussis* antigens, Pertussis Toxin (PT), Filamentous haemagglutinin (FHA), the 69kDa outer membrane protein (pertactin) and fimbrial agglutinogens (see Table 1 below. The Tables appear at the end of the specification).

Pertussis Toxin

Pertussis toxin is an exotoxin which is a member of the A/B family of bacterial toxins with ADP-ribosyltransferase activity (ref. 8). The A-moiety of these toxins exhibit the ADP-ribosyltransferase activity and the B portion mediates binding of the toxin to host cell receptors and the translocation of A to its site of action. PT also facilitates the adherence of *B. pertussis* to ciliated epithelial cells (ref. 9) and also plays a role in the invasion of macrophages by *B. pertussis* (ref. 10).

All acellular pertussis vaccines have included PT, which has been proposed as a major virulence factor and protective antigen (ref. 11, 12). Natural infection with *B. pertussis* generates both humoral and cell-mediated responses to PT (refs. 13 to 17). Infants have transplacentally-derived anti-PT antibodies (refs. 16,

18) and human colostrum containing anti-PT antibodies was effective in the passive protection of mice against aerosol infection (ref. 19). A cell-mediated immune (CMI) response to PT subunits has been demonstrated after immunization with an acellular vaccine (ref. 20) and a CMI response to PT was generated after whole-cell vaccination (ref. 13). Chemically-inactivated PT in whole-cell or component vaccines is protective in animal models and in humans (ref. 21). Furthermore, monoclonal antibodies specific for subunit S1 protect against *B. pertussis* infection (refs. 22 and 23).

The main pathophysiological effects of PT are due to its ADP-ribosyltransferase activity. PT catalyses the transfer of ADP-ribose from NAD to the G_i guanine nucleotide-binding protein, thus disrupting the cellular adenylate cyclase regulatory system (ref. 24). PT also prevents the migration of macrophages and lymphocytes to sites of inflammation and interferes with the neutrophil-mediated phagocytosis and killing of bacteria (ref. 25). A number of *in vitro* and *in vivo* assays have been used to assess the enzymatic activity of S1 and/or PT, including the ADP-ribosylation of bovine transducin (ref. 26), the Chinese hamster ovary (CHO) cell clustering assay (ref. 27), histamine sensitization (ref. 28), leukocytosis, and NAD glycohydrolase. When exposed to PT, CHO cells develop a characteristic clustered morphology. This phenomenon is dependent upon the binding of PT, and subsequent translocation and ADP-ribosyltransferase activity of S1 and thus the CHO cell clustering assay is widely used to test the integrity and toxicity of PT holotoxins.

Filamentous Haemagglutinin

Filamentous haemagglutinin is a large (220 kDa) non-toxic polypeptide which mediates attachment of *B. pertussis* to ciliated cells of the upper respiratory tract during bacterial colonization (refs. 9, 29).

Natural infection induces anti-FHA antibodies and cell mediated immunity (refs. 13, 15, 17, 30 and 31). Anti-FHA antibodies are found in human colostrum and are also transmitted transplacentally (refs. 17, 18 and 19).
5 Vaccination with whole-cell or acellular pertussis vaccines generates anti-FHA antibodies and acellular vaccines containing FHA also induce a CMI response to FHA (refs. 20, 32). FHA is a protective antigen in a mouse respiratory challenge model after active or passive
10 immunization (refs. 33, 34). However, alone FHA does not protect in the mouse intracerebral challenge potency assay (ref. 28).

69 kDa Outer Membrane Protein (Pertactin)

The 69kDa protein is an outer membrane protein which
15 was originally identified from *B. bronchiseptica* (ref. 35). It was shown to be a protective antigen against *B. bronchiseptica* and was subsequently identified in both *B. pertussis* and *B. parapertussis*. The 69kDa protein binds directly to eukaryotic cells (ref. 36) and natural
20 infection with *B. pertussis* induces an anti-P.69 humoral response (ref. 14) and P.69 also induces a cell-mediated immune response (ref. 17, 37, 38). Vaccination with whole-cell or acellular vaccines induces anti-P.69 antibodies (refs. 32, 39) and acellular vaccines induce
25 P.69 CMI (ref. 39). Pertactin protects mice against aerosol challenge with *B. pertussis* (ref. 40) and in combination with FHA, protects in the intracerebral challenge test against *B. pertussis* (ref. 41). Passive transfer of polyclonal or monoclonal anti-P.69 antibodies
30 also protects mice against aerosol challenge (ref. 42).

Agglutinogens

Serotypes of *B. pertussis* are defined by their
agglutinating fimbriae. The WHO recommends that whole-cell vaccines include types 1, 2 and 3 agglutinogens
35 (Aggs) since they are not cross-protective (ref. 43). Agg 1 is non-fimbrial and is found on all *B. pertussis*

strains while the serotype 2 and 3 Aggs are fimbrial. Natural infection or immunization with whole-cell or acellular vaccines induces anti-Agg antibodies (refs. 15, 32). A specific cell-mediated immune response can be generated in mice by Agg 2 and Agg 3 after aerosol infection (ref. 17). Aggs 2 and 3 are protective in mice against respiratory challenge and human colostrum containing anti-agglutinogens will also protect in this assay (refs. 19, 44, 45).

10 **Acellular Vaccines**

The first acellular vaccine developed was the two-component PT + FHA vaccine (JN1H 6) of Sato et al. (ref. 46). This vaccine was prepared by co-purification of PT and FHA antigens from the culture supernatant of *B. pertussis* strain Tohama, followed by formalin toxoiding. Acellular vaccines from various manufacturers and of various compositions have been used successfully to immunize Japanese children against whooping cough since 1981 resulting in a dramatic decrease in incidence of disease (ref. 47). The JN1H 6 vaccine and a mono-component PT toxoid vaccine (JN1H 7) were tested in a large clinical trial in Sweden in 1986. Initial results indicated lower efficacy than the reported efficacy of a whole-cell vaccine, but follow-up studies have shown it to be more effective against milder disease diagnosed by serological methods (refs. 48, 49, 50, 51). However, there was evidence for reversion to toxicity of formalin-inactivated PT in these vaccines. These vaccines were also found to protect against disease rather than infection.

A number of new acellular pertussis vaccines are currently being assessed which include combinations of PT, FHA, P.69, and/or agglutinogens and these are listed in Table 1. Several techniques of chemical detoxication have been used for PT including inactivation with

formalin (ref. 46), glutaraldehyde (ref. 52), hydrogen peroxide (ref. 53), and tetranitromethane (ref. 54).

Thus, current commercially-available acellular pertussis vaccines may not contain appropriate formulations of appropriate antigens in appropriate immunogenic forms to achieve a desired level of efficacy in a pertussis-susceptible human population.

It would be desirable to provide efficacious acellular pertussis vaccines containing selected relative amounts of selected antigens and methods of production thereof.

SUMMARY OF THE INVENTION

The present invention is directed towards acellular pertussis vaccine preparations, components thereof, methods of preparation of such vaccines and their components, and methods of use thereof.

In a further aspect of the invention, there is provided an immunogenic composition comprising the fimbrial agglutinin preparation as provided herein. The immunogenic composition may be formulated as a vaccine for *in vivo* use for protecting a host immunized therewith from disease caused by *Bordetella* and may comprise at least one other *Bordetella* antigen. The at least one other *Bordetella* antigen may be filamentous haemagglutinin, the 69 kDa outer membrane protein adenylate cyclase, *Bordetella* lipooligosaccharide, outer membrane proteins and pertussis toxin or a toxoid thereof, including genetically detoxified analogs thereof.

In a further aspect of the invention, the immunogenic composition as provided herein may comprise at least one non-*Bordetella* immunogen. Such non-*Bordetella* immunogen may be diphtheria toxoid, tetanus toxoid, capsular polysaccharide of *Haemophilus*, outer membrane protein of *Haemophilus*, hepatitis B surface antigen, polio, mumps, measles and/or rubella.

The immunogenic compositions as provided herein may further comprise an adjuvant and such adjuvant may be aluminum phosphate, aluminum hydroxide, Quil A, QS21, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid or a lipoprotein.

In accordance with one aspect of the present invention, there is provided a vaccine composition for protecting an at-risk human population against a case of disease caused by infection by B. pertussis, which comprises pertussis toxoid, filamentous haemagglutinin, pertactin and agglutinogens in purified form in selected relative amounts to confer protection to the extent of at least about 70% of members of the at-risk population.

Such vaccine composition may contain about 5 to about 30 μg nitrogen of pertussis toxoid, about 5 to about 30 μg nitrogen of filamentous haemagglutinin, about 3 to about 15 μg nitrogen of pertactin and about 1 to about 10 μg nitrogen of agglutinogens.

In one specific embodiment, the vaccine may comprise pertussis toxoid, filamentous haemagglutinin, the 69 kDa protein and filamentous agglutinogens of *Bordetella* at a weight ratio of about 10:5:5:3 as provided by about 10 μg of pertussis toxoid, about 5 μg of filamentous haemagglutinin, about 5 μg of 69 kDa protein and about 3 μg of fimbrial agglutinogens in a single human dose. In a further particular embodiment, the vaccine may comprise pertussis toxoid, filamentous haemagglutinin, 69 kDa protein and fimbrial agglutinogens in a weight ratio of about 20:20:5:3 as provided by about 20 μg of pertussis toxoid, about 20 μg of filamentous haemagglutinin, about 5 μg of 69 kDa protein and about 3 μg of fimbrial agglutinogens in a single human dose. In a yet further particular embodiment, the vaccine may comprise pertussis toxoid filamentous haemagglutinin, 69 kDa protein and fimbrial agglutinogens in a weight ratio of about

20:10:10:6 as provided by about 20 µg of pertussis toxoid, about 10 µg of filamentous haemagglutinin, about 10 µg of 69 kDa protein and about 6 µg of fimbrial agglutinogens in a single human dose.

- 5 The extent of protection to the at-risk human population afforded by the vaccine composition of the invention may be at least about 80%, preferably about 85%, for a case of spasmodic cough of duration at least 21 days and culture-confirmed bacterial infection. The
10 extent of protection to the at-risk human population may be at least about 70% for a case of mild pertussis having a cough of at least one day duration.

- The agglutinogens component of the vaccine preferably comprise fimbrial agglutininogen 2 (Agg 2) and
15 fimbrial agglutininogen 3 (Agg 3) substantially free from agglutininogen 1. The weight ratio of Agg 2 to Agg 3 may be from about 1.5:1 to about 2:1.

- The vaccine provided herein may be combined with tetanus toxoid and diphtheria toxoid to provide a DTP
20 vaccine. In one embodiment, the vaccine contains about 15 Lfs of diphtheria toxoid and about 5 Lfs of tetanus toxoid.

 In addition, the vaccine may also comprise an adjuvant, particularly alum.

- 25 In a further aspect of the present invention, there is provided a method of immunizing an at-risk human population against disease caused by infection by B. pertussis, which comprises administering to members of the at-risk human population an immunoeffective amount of
30 the vaccine composition provided herein to confer protection to the extent of at least about 70% of the members of the at-risk population.

- Advantages of the present invention include an improved acellular pertussis vaccine composition of
35 increased efficacy.

The present invention further provides, in an additional aspect, purified forms of pertussis toxin, filamentous haemagglutinin, pertactin and fimbrial agglutinogens of *B. pertussis* when used in the manufacture of a vaccine composition for administration to an at-risk human population to confer protection to the extent of at least about 70% of the members of said at-risk human population.

In such use, there may be employed in the manufacture of a single human dose of the vaccine composition from about 30 μ g of nitrogen of pertactin and about 1 to about 10 μ g of nitrogen of the fimbrial agglutinogens. In particular, the vaccine composition as provided herein have been selected by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States Government for evaluation in a double-blind, human efficacy clinical trial, thereby establishing a sufficient basis to those especially skilled in the art that the compositions will be effective to some degree in preventing the stated disease (pertussis). The subject of that trial (being a vaccine as provided herein) has met the burden of being reasonably predictive of utility.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the following detailed description and Examples with reference to the accompanying drawing in which:

Figure 1 is a schematic flow sheet of a procedure for the isolation of an agglutinin preparation from a *Bordetella* strain.

DETAILED DESCRIPTION OF THE INVENTION

Referring to Figure 1, there is illustrated a flow sheet of a method for preparing an agglutinin preparation from a *Bordetella* strain. As seen in Figure

1, a *Bordetella* cell paste containing the agglutinogens, such as *B. pertussis* cell paste, is extracted with, for example, a urea-containing buffer, such as 10 mM potassium phosphate, 150 mM NaCl and 4M urea, to
5 selectively extract the agglutinogens from the cell paste to produce a first supernatant (sp1) containing agglutinogens and a first residual precipitate (ppt1). The first supernatant (sp1) is separated from the first residual precipitate (ppt1) such as by centrifugation.
10 The residual precipitate (ppt1) is discarded. The clarified supernatant (sp1) then may be concentrated and diafiltered against, for example, 10mM potassium phosphate/150mM NaCl/0.1% Triton X-100 using, for example, a 100 to 300 kDa NMWL membrane filter.
15 The first supernatant then is incubated at a temperature and for a time to produce a clarified supernatant (sp2) containing agglutinogens and a second discard precipitate (ppt2) containing non-agglutininogen contaminants. Appropriate temperatures include about
20 50°C to about 100°C, including about 75° to about 85°C, and appropriate incubation times include about 1 to about 60 minutes. The clarified supernatant then is concentrated by, for example, the addition of polyethylene glycol of molecular weight about 8000 (PEG
25 8000) to a final concentration of about $4.5 \pm 0.2\%$ and stirring gently for a minimum of about 30 minutes to produce a third precipitate (ppt3) which may be collected by centrifugation. The remaining supernatant sp3 is discarded.
30 This third precipitate (ppt3) is extracted with, for example, a buffer comprising 10mM potassium phosphate/150 mM NaCl to provide the crude fimbrial agglutininogen-containing solution. 1M potassium phosphate may be added to the crude fimbrial solution to make it about 100mM
35 with respect to potassium phosphate. Alternatively, the clarified supernatant of heat-treated fimbrial

agglutinogens can be purified without precipitation by gel-filtration chromatography using a gel, such as Sepharose CL6B. The fimbrial agglutinogens in the crude solution then are purified by column chromatography, such as, by passing through a PEI silica column, to produce the fimbrial agglutinin preparation in the run-through.

This fimbrial agglutinin containing run-through may be further concentrated and diafiltered against, for example, a buffer containing 10mM potassium phosphate/150mM NaCl using a 100-300 kDa NMWL membrane. The agglutinin preparation may be sterilized by filtration through a $\leq 0.22 \mu\text{M}$ membrane filter, to provide the final purified fimbrial agglutinin preparation containing fimbrial agglutinin 2 and 3.

An agglutinin preparation from a *Bordetella* strain may comprise fimbrial agglutinin 2 (Agg 2) and fimbrial agglutinin 3 (Agg 3) substantially free from agglutinin 1. The weight ratio of Agg 2 to Agg 3 may be from about 1.5:1 to about 2:1. Such fimbrial agglutinin preparations may be produced by the method as provided herein and described in detail above. The present invention also extends to immunogenic compositions (including vaccines) comprising the fimbrial agglutinin preparations provided as described above. Such vaccines contain other *Bordetella* immunogens, including filamentous haemagglutinin, the 69 kDa outer membrane protein and pertussis toxin or a toxoid thereof, including genetically detoxified analogs of PT as described in, for example, ref. 68.

Such vaccines may include non-*Bordetella* immunogens including diphtheria toxoid, tetanus toxoid, capsular polysaccharide of *Haemophilus*, outer membrane protein of *Haemophilus*, hepatitis B surface antigen, polio, mumps, measles and rubella.

Each of the *Bordetella* antigens is individually absorbed to adjuvant (such as alum) to provide for

convenient and rapid production of vaccines containing selected relative amounts of antigens in vaccines as provided herein in order to confer protection to an extent of at least about 70% of the members of an at risk population, preferably at least about 80% of such population.

In selected embodiments, the invention provides vaccines with the following characteristics (μ g proteins used herein are based on Kjeldahl test results performed on purified concentrates and are expressed as μ g of protein nitrogen), all of which may be administered by intramuscular injection:

(a) CP_{10/5/5/3}DT

One formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{10/5/5/3}DT. Each 0.5 ml human dose of CP_{10/5/5/3}DT was formulated to contain about:

10 μ g	Pertussis toxoid (PT)
5 μ g	Filamentous haemagglutinin (FHA)
5 μ g	Fimbrial agglutinogens 2 and 3 (FIMB)
3 μ g	69 kDa outer membrane protein
15 Lf	Diphtheria toxoid
5 Lf	Tetanus toxoid
1.5 mg	Aluminum phosphate
0.6%	2-phenoxyethanol, as preservative

(b) CP_{20/20/5/3}DT

Another formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{20/20/5/3}DT. Each 0.5 ml human dose of CP_{20/20/5/3}DT was formulated to contain about:

20 μ g	Pertussis toxoid (PT)
20 μ g	Filamentous haemagglutinin (FHA)
5 μ g	Fimbrial agglutinogens 2 and 3 (FIMB)
3 μ g	69 kDa outer membrane protein
15 Lf	Diphtheria toxoid
5 Lf	Tetanus toxoid
1.5 mg	Aluminum phosphate

0.6% 2-phenoxyethanol, as preservative

(c) CP_{10/5/5}DT

One formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed
5 CP_{10/5/5}DT. Each 0.5 mL human dose of CP_{10/5/5} was formulated to contain about:

10 µg Pertussis toxoid (PT)
5 µg Filamentous haemagglutinin (FHA)
5 µg Fimbrial agglutinogens 2 and 3 (FIMB)

10 15 Lf Diphtheria toxoid
5 Lf Tetanus toxoid

1.5 mg Aluminum phosphate

0.6% 2-phenoxyethanol as preservative

(d) CP_{20/10/10/6}DT

15 A further formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{20/10/10/6}DT. Each 0.5 ml human dose of CP_{20/10/10/6}DT was formulated to contain about:

20 µg Pertussis toxoid (PT)
20 10 µg Filamentous haemagglutinin (FHA)
10 µg Fimbrial agglutinogens 2 and 3 (FIMB)
6 µg 69 kDa outer membrane protein (69kDa)

15 Lf Diphtheria toxoid
5 Lf Tetanus toxoid

25 1.5 mg Aluminum phosphate

0.6% 2-phenoxyethanol, as preservative

The other *Bordetella* immunogens, pertussis toxin (including genetically detoxified analogs thereof, as described in, for example, Klein et al, U.S. Patent No.
30 5,085,862 assigned to the assignee hereof and incorporated herein by reference thereto), FHA and the 69 kDa protein may be produced by a variety of methods such as described below:

Purification of PT

35 PT may be isolated from the culture supernatant of a *B. pertussis* strain using conventional methods. For example, the method of Sekura et al (ref. 55) may be

used. PT is isolated by first absorbing culture supernatant onto a column containing the dye-ligand gel matrix, Affi-Gel Blue (Bio-Rad Laboratories, Richmond, CA). PT is eluted from this column by high salt, such as, 0.75 M magnesium chloride and, after removing the salt, is passed through a column of fetuin-Sepharose affinity matrix composed of fetuin linked to cyanogen bromide-activated Sepharose. PT is eluted from the fetuin column using 4M magnesium salt.

Alternatively, the method of Irons et al (ref. 56) may be used. Culture supernatant is absorbed onto a CNBr-activated Sepharose 4B column to which haptoglobin is first covalently bound. The PT binds to the absorbent at pH 6.5 and is eluted from the column using 0.1M Tris/0.5M NaCl buffer by a stepwise change to pH 10.

Alternatively, the method described in U.S. Patent No. 4,705,686 granted to Scott et al on November 10, 1987 and incorporated herein by reference thereto may be used. In this method culture supernatants or cellular extracts of *B. pertussis* are passed through a column of an anion exchange resin of sufficient capacity to adsorb endotoxin but permit *Bordetella* antigens to flow through or otherwise be separated from the endotoxin.

Alternatively, PT may be purified by using perlite chromatography, as described in EP Patent No. 336 736, assigned to the assignee thereof and incorporated herein by reference thereto.

Detoxification of PT

PT is detoxified to remove undesired activities which could cause side reactions of the final vaccine. Any of a variety of conventional chemical detoxification methods can be used, such as treatment with formaldehyde, hydrogen peroxide, tetranitro-methane, or glutaraldehyde.

For example, PT can be detoxified with glutaraldehyde using a modification of the procedure described in Munoz et al (ref. 57). In this

detoxification process purified PT is incubated in a solution containing 0.01 M phosphate buffered saline. The solution is made 0.05% with glutaraldehyde and the mixture is incubated at room temperature for two hours, and then made 0.02 M with L-lysine. The mixture is further incubated for two hours at room temperature and then dialyzed for two days against 0.01 M PBS. In a particular embodiment, the detoxification process of EP Patent No. 336 736 may be used. Briefly PT may be detoxified with glutaraldehyde as follows:

Purified PT in 75mM potassium phosphate at pH 8.0 containing 0.22M sodium chloride is diluted with an equal volume of glycerol to protein concentrations of approximately 50 to 400 μ g/ml. The solution is heated to 37°C and detoxified by the addition of glutaraldehyde to a final concentration of 0.5% (w/v). The mixture is kept at 37°C for 4 hrs and then aspartic acid (1.5 M) is added to a final concentration of 0.25 M. The mixture is incubated at room temperature for 1 hour and then diafiltered with 10 volumes of 10 mM potassium phosphate at pH 8.0 containing 0.15M sodium chloride and 5% glycerol to reduce the glycerol and to remove the glutaraldehyde. The PT toxoid is sterile-filtered through a 0.2 μ M membrane.

If recombinant techniques are used to prepare a PT mutant molecule which shows no or little toxicity, for use as the toxoided molecule, chemical detoxification is not necessary.

Purification of FHA

FHA may be purified from the culture supernatant essentially as described by Cowell et al (ref. 58). Growth promoters, such as methylated beta-cyclodextrins, may be used to increase the yield of FHA in culture supernatants. The culture supernatant is applied to a hydroxylapatite column. FHA is adsorbed onto the column, but PT is not. The column is extensively washed with

Triton X-100 to remove endotoxin. FHA is then eluted using 0.5M NaCl in 0.1M sodium phosphate and, if needed, passed through a fetuin-Sepharose column to remove residual PT. Additional purification can involve passage
5 through a Sepharose CL-6B column.

Alternatively, FHA may be purified using monoclonal antibodies to the antigen, where the antibodies are affixed to a CNBr-activated affinity column (ref. 59).

Alternatively, FHA may be purified by using perlite
10 chromatography as described in the above-mentioned EP 336 736.

Purification of 69 kDa Outer Membrane Protein (pertactin)

The 69 kDa outer membrane protein (69K or pertactin)
15 may be recovered from bacterial cells by first inactivating the cells with a bacteriostatic agent, such as thimerosal, as described in published EP 484 621 and incorporated herein by reference thereto. The inactivated cells are suspended in an aqueous medium,
20 such as PBS (pH 7 to 8) and subjected to repeated extraction at elevated temperature (45 to 60°C) with subsequent cooling to room temperature or 4°C. The extractions release the 69K protein from the cells. The material containing the 69K protein is collected by
25 precipitation and passed through an Affi-gel Blue column. The 69K protein is eluted with a high concentration of salt, such as 0.5M magnesium chloride. After dialysis, it is passed through a chromatofocusing support.

Alternatively, the 69 kDa protein may be purified
30 from the culture supernatant of a *B. pertussis* culture, as described in published PCT Application WO 91/15505, in the name of the assignee hereof and incorporated herein by reference thereto.

Other appropriate methods of purification of the 69
35 kDa outer membrane protein from *B. pertussis* are described in U.S. Patent No. 5,276,142, granted to Gotto

et al on January 4, 1984 and in U.S. Patent No. 5,101,014, granted to Burns on March 31, 1992.

A number of clinical trials were performed in humans as described herein to establish the safety, non-reactogenicity and utility of component vaccines for protection against pertussis. In particular, immune responses to each of the antigens contained in the vaccines (as shown, for example, in Table 3 below) were obtained. One particular acellular pertussis vaccine CP_{10/5/5/3}DT was analyzed in a large placebo-controlled, multi-centre, double-randomized clinical trial in an at-risk human population to estimate the efficacy of the vaccine against typical pertussis.

The case definition for typical pertussis disease was:

Twenty-one days or more of spasmodic cough, and either culture-confirmed B. pertussis,
or
serological evidence of Bordetella specific infection indicated by a 100% IgG or IgA antibody rise in ELISA against FHA or PT in paired sera,
or
if serological data is lacking, the study child has been in contact with a case of culture-confirmed B. pertussis in the household with onset of cough within 28 days before or after the onset of cough in the study child.

The results of this study showed CP_{10/5/5/3}DT to be about 85% efficacious in preventing pertussis as defined in the case definition for typical pertussis disease as described above. In the same study, a two-component pertussis acellular vaccine containing only PT and FHA was about 58% efficacious and a whole-cell pertussis vaccine was about 48% efficacious (see Table 4 below). In addition, the CP_{10/5/5/3}DT vaccine prevented mild pertussis defined as a cough of at least one day duration to an efficacy of about 77%. In particular, the profile of immune response obtained was substantially the same as that obtained following immunization with whole-cell

pertussis vaccines which are reported to be highly efficacious against pertussis.

Vaccine Preparation and Use

Thus, immunogenic compositions, suitable to be used
5 as vaccines, may be prepared from the *Bordetella*
immunogens as disclosed herein. The vaccine elicits an
immune response in a subject which produces antibodies
that may be opsonizing or bactericidal. Should the
10 vaccinated subject be challenged by *B. pertussis*, such
antibodies bind to and inactivate the bacteria.
Furthermore, opsonizing or bactericidal antibodies may
also provide protection by alternative mechanisms.

Immunogenic compositions including vaccines may be
prepared as injectibles, as liquid solutions or
15 emulsions. The *Bordetella* immunogens may be mixed with
pharmaceutically acceptable excipients which are
compatible with the immunogens. Such excipients may
include water, saline, dextrose, glycerol, ethanol, and
combinations thereof. The immunogenic compositions
20 and vaccines may further contain auxiliary substances,
such as wetting or emulsifying agents, pH buffering
agents, or adjuvants to enhance the effectiveness
thereof. Immunogenic compositions and vaccines may be
administered parenterally, by injection subcutaneously or
25 intramuscularly. The immunogenic preparations and
vaccines are administered in a manner compatible with the
dosage formulation, and in such amount as will be
therapeutically effective, immunogenic and protective.
The quantity to be administered depends on the subject to
30 be treated, including, for example, the capacity of the
immune system of the individual to synthesize antibodies,
and, if needed, to produce a cell-mediated immune
response. Precise amounts of active ingredient required
to be administered depend on the judgment of the
35 practitioner. However, suitable dosage ranges are
readily determinable by one skilled in the art and may be

of the order of micrograms of the immunogens. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may
5 also depend on the route of administration and will vary according to the size of the host.

The concentration of the immunogens in an immunogenic composition according to the invention is in general about 1 to about 95%. A vaccine which contains
10 antigenic material of only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or
15 from various strains of the same pathogen, or from combinations of various pathogens.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants, commonly used as 0.005 to 0.5 percent solution in phosphate
20 buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of
25 antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been used
30 for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-
35 covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have

been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established and, more recently, a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is well established for some applications, it has limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgG1 isotype in the mouse, which may not be optimal for protection by some vaccinal agents.

A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are often emulsified in adjuvants. Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations (Freund's complete adjuvant, FCA), cytotoxicity (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and MDP). Although FCA is an excellent adjuvant and widely used in research, it is not licensed for use in human or veterinary vaccines because of its toxicity.

Desirable characteristics of ideal adjuvants include:

- (1) lack of toxicity;
- (2) ability to stimulate a long-lasting immune
5 response;
- (3) simplicity of manufacture and stability in long-term storage;
- (4) ability to elicit both CMI and HIR to antigens administered by various routes;
- 10 (5) synergy with other adjuvants;
- (6) capability of selectively interacting with populations of antigen presenting cells (APC):
- (7) ability to specifically elicit appropriate T_H1 or T_H2 cell-specific immune responses; and
- 15 (8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

U.S. Patent No. 4,855,283 granted to Lockhoff et al on August 8, 1989 which is incorporated herein by
20 reference thereto teaches glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants. Thus, Lockhoff et al. (U.S. Patent No.
25 4,855,283 and ref. 60) reported that N-glycolipid analogs displaying structural similarities to the naturally-occurring glycolipids, such as glycosphingolipids and glycoglycerolipids, are capable of eliciting strong immune responses in both herpes simplex virus vaccine and
30 pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

35 U.S. Patent No. 4,258,029 granted to Moloney, assigned to the assignee hereof and incorporated herein

by reference thereto, teaches that octadecyl tyrosine hydrochloride (OTH) functions as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Also,
5 Nixon-George et al. (ref. 61), reported that octodecyl esters of aromatic amino acids complexed with a recombinant hepatitis B surface antigen, enhanced the host immune responses against hepatitis B virus.

EXAMPLES

10 The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for the purposes of illustration and are not intended to limit the scope of
15 the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

20 Methods of protein biochemistry, fermentation and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

25 Example 1:

This Example describes the growth of *Bordetella pertussis*.

Master Seed:

Master seed cultures of a *Bordetella pertussis* strain were held as freeze-dried seed lots, at 2°C to 8°C.

5 **Working Seed:**

The freeze-dried culture was recovered in Hornibrook medium and used to seed Bordet-Gengou Agar (BGA) plates. Hornibrook medium has the following composition:

	<u>Component</u>	<u>for 1 litre</u>
10	Casein hydrolysate (charcoal treated)	10.0 g
	Nicotinic acid	0.001 g
	Calcium chloride	0.002 g
	Sodium chloride	5.0 g
	Magnesium chloride hexahydrate	0.025 g
15	Potassium chloride	0.200 g
	Potassium phosphate dibasic	0.250 g
	Starch	1.0 g
	Distilled water	to 1.0 litre

The pH is adjusted to 6.9 ± 0.1 with 1% sodium carbonate solution. The medium is dispensed into tubes and sterilized by steaming in the autoclave for 20 minutes and autoclaving for 20 minutes at 121°C to 124°C. The seed was subcultured twice, firstly on BGA plates then on Component Pertussis Agar (CPA). Component Pertussis Agar

25 (CPA) has the following composition:

	NaCl	2.5 g/L
	KH ₂ PO ₄	0.5 g/L
	KCl	0.2 g/L
	MgCl ₂ (H ₂ O) ₆	0.1 g/L
30	Tris base	1.5 g/L
	Casamino acids	10.0 g/L
	NaHGlutamate	10.0 g/L
	Conc. HCl	to pH 7.2
	Agar	15.0 g/L
35	Growth factors (CPGF)	10.0 mL/L

Component Pertussis Growth Factors (CPGF) - 100X have the following composition:

	L-cysteine HCl	4.0 g/L
	Niacin	0.4 g/L
5	Ascorbic acid	40.0 g/L
	Glutathione, reduced	15.0 g/L
	Fe ₂ SO ₄ , (H ₂ O) ₇	1.0 g/L
	Dimethyl-β-cyclodextrin	100 g/L
	CaCl ₂ (H ₂ O) ₂	2.0 g/L

- 10 The final culture was suspended in Pertussis Seed Suspension Buffer (CPSB), dispensed into 2 to 4 ml aliquots and stored frozen at -60°C to -85°C. Pertussis Seed Suspension Buffer (PSSB) has the following composition:

15	Casamino acids	10.0 g/L
	Tris base	1.5 g/L
	Anhydrous glycerol	100 mL/L
	Conc. HCl	to pH 7.2

These glycerol suspensions provided the starting material

- 20 for the preparation of the working seed.

Cultivation Process:

- Propagation of the working seed was conducted in Component Pertussis Agar Roux bottles for 4 to 7 days at 34°C to 38°C. Following this cultivation, cells were
 25 washed off agar with Component Pertussis Broth (CPB). Samples were observed by Gram stain, for culture purity and opacity.

- Cells were transferred to 4 litre conical flasks containing CPB and incubated at 34°C to 38°C for 20 to 26
 30 hours with shaking. Samples were observed by Gram stain and culture purity was checked. Flasks were pooled and the suspension was used to seed two fermenters containing CPB (10 litre volume starting at OD₆₀₀ 0.1-0.4). The seed was grown to a final OD₆₀₀ of 5.0 to 10.0. Samples were
 35 tested by Gram strain, for culture purity, by antigen specific ELISAs and for sterility.

Example 2:

This Example describes the purification of antigens from the *Bordetella pertussis* cell culture.

Production of Broth and Cell Concentrates:

5 Bacterial suspension was grown in two production fermenters, at 34°C to 37°C for 35 to 50 hours. The fermenters were sampled for media sterility testing. The suspension was fed to a continuous-flow disk-stack centrifuge (12,000 x g) to separate cells from the broth.
10 Cells were collected to await extraction of fimbriae component. The clarified liquor was passed through $\leq 0.22 \mu\text{m}$ membrane filter. The filtered liquor was concentrated by ultra filtration using a 10 to 30 kDa nominal molecular weight limit (NMWL) membrane. The
15 concentrate was stored to await separation and purification of the Pertussis Toxin (PT), Filamentous haemagglutinin (FHA) and 69 kDa (pertactin) components.

Separation of the Broth Components:

The broth components (69 kDa, PT and FHA) were
20 separated and purified by perlite chromatography and selective elution steps, essentially as described in EP Patent No. 336 736 and applicants published PCT Application No. WO 91/15505, described above. The specific purification operations effected are described
25 below.

Pertussis Toxin (PT):

The perlite column was washed with 50 mM Tris, 50 mM Tris/0.5% Triton X-100 and 50 mM Tris buffers. The PT fraction was eluted from the perlite column with 50 mM
30 Tris/0.12M NaCl buffer.

The PT fraction from the perlite chromatography was loaded onto a hydroxylapatite column and then washed with 30mM potassium phosphate buffer. PT was eluted with 75mM potassium phosphate/225 mM NaCl buffer. The column was
35 washed with 200 mM potassium phosphate/0.6M NaCl to obtain the FHA fraction which was discarded. Glycerol

was added to the purified PT to 50% and the mixture was stored at 2°C to 8°C until detoxification, within one week.

Filamentous Haemagglutinin (FHA):

5 The FHA fraction was eluted from the perlite column with 50mM Tris/0.6M NaCl. Filamentous haemagglutinin was purified by chromatography over hydroxylapatite. The FHA fraction from the perlite column was loaded onto a hydroxylapatite column then washed with 30 mM potassium
10 phosphate containing 0.5% Triton X-100, followed by 30 mM potassium phosphate buffer. The PT fraction was eluted with 85 mM potassium phosphate buffer and discarded. The FHA fraction was then eluted with 200 mM potassium phosphate/0.6M NaCl and stored at 2°C to 8°C until
15 detoxification within one week.

69 kDa (pertactin):

The broth concentrate was diluted with water for injection (WFI) to achieve a conductivity of 3 to 4 mS/cm and loaded onto a perlite column at a loading of 0.5 to
20 3.5 mg protein per ml perlite. The run-through (69 kDa Component Fraction) was concentrated by ultrafiltration using a 10 to 30 kDa NMWL membrane. Ammonium sulphate was added to the run-through concentrate to 35% ± 3% (w/v) and the resulting mixture stored at 2°C to 8°C for
25 4 ± 2 days or centrifuged (7,000 x g) immediately. Excess supernatant was decanted and the precipitate collected by centrifugation (7,000 x g). The 69 kDa pellet was either stored frozen at -20°C to -30°C or dissolved in Tris or phosphate buffer and used
30 immediately.

The 69 kDa outer membrane protein obtained by the 35% (w/v) ammonium sulphate precipitation of concentrated perlite run-through was used for the purification. Ammonium sulphate (100 ± 5 g per litre) was added to the
35 69 kDa fraction and the mixture stirred for at least 2 hours at 2°C to 8°C. The mixture was centrifuged (7,000

x g) to recover the supernatant. Ammonium sulphate (100 to 150 g per liter) was added to the supernatant and the mixture stirred for at least 2 hours at 2°C to 8°C. The mixture was centrifuged (7,000 x g) to recover the pellet, which was dissolved in 10 mM Tris, HCl, pH 8. The ionic strength of the solution was adjusted to the equivalent of 10 mM Tris HCl (pH 8), containing 15 mM ammonium sulphate.

The 69 kDa protein was applied to a hydroxylapatite column connected in tandem with a Q-Sepharose column. The 69 kDa protein was collected in the run-through, was flushed from the columns with 10 mM Tris, HCl (pH 8), containing 15 mM ammonium sulphate and pooled with 69 kDa protein in the run-through. The 69 kDa protein pool was diafiltered with 6 to 10 volumes of 10 mM potassium phosphate (pH 8), containing 0.15M NaCl on a 100 to 300 kDa NMWL membrane. The ultra filtrate was collected and the 69 kDa protein in the ultra filtrate concentrated.

The 69 kDa protein was solvent exchanged into 10 mM Tris HCl (pH8), and adsorbed onto Q-Sepharose, washed with 10 mM Tris HCl (pH 8)/5 mM ammonium sulphate. The 69 kDa protein was eluted with 50 mM potassium phosphate (pH 8). The 69 kDa protein was diafiltered with 6 to 10 volumes of 10 mM potassium phosphate (pH 8) containing 0.15M NaCl on a 10 to 30 kDa NMWL membrane. The 69 kDa protein was sterile filtered through a $\leq 0.22 \mu\text{m}$ filter. This sterile bulk was stored at 2°C to 8°C and adsorption was performed within three months.

Fimbrial Agglutinogens:

The agglutinogens were purified from the cell paste following separation from the broth. The cell paste was diluted to a 0.05 volume fraction of cells in a buffer containing 10 mM potassium phosphate, 150mM NaCl and 4M urea and was mixed for 30 minutes. The cell lysate was clarified by centrifugation (12,000 x g) then concentrated and diafiltered against 10mM potassium

phosphate/150mM NaCl/0.1% Triton X-100 using a 100 to 300 kDa NMWL membrane filter.

The concentrate was heat treated at 80°C for 30 min then reclarified by centrifugation (9,000 x g). PEG 8000
5 was added to the clarified supernatant to a final concentration of 4.5% \pm 0.2% and stirred gently for a minimum of 30 minutes. The resulting precipitate was collected by centrifugation (17,000 x g) and the pellet extracted with 10 mM potassium phosphate/150mM NaCl
10 buffer to provide a crude fimbrial agglutinin solution. The fimbrial agglutinogens were purified by passage over PEI silica. The crude solution was made 100 mM with respect to potassium phosphate using 1M potassium phosphate buffer and passed through the PEI silica
15 column.

The run-through from the columns was concentrated and diafiltered against 10mM potassium phosphate/150mM NaCl buffer using a 100 to 300 kDa NMWL membrane filter. This sterile bulk is stored at 2°C to 8°C and adsorption
20 performed within three months. The fimbrial agglutinin preparation contained fimbrial Agg 2 and fimbrial Agg 3 in a weight ratio of about 1.5 to about 2:1 and was found to be substantially free from Agg 1.

Example 3:

25 This Example describes the toxoiding of the purified *Bordetella pertussis* antigens, PT and FHA.

PT, prepared in pure form as described in Example 2, was toxoided by adjusting the glutaraldehyde concentration in the PT solution to 0.5% \pm 0.1% and
30 incubating at 37°C \pm 3°C for 4 hours. The reaction was stopped by adding L-aspartate to 0.21 \pm 0.02M. The mixture was then held at room temperature for 1 \pm 0.1 hours and then at 2°C to 8°C for 1 to 7 days.

The resulting mixture was diafiltered against 10mM
35 potassium phosphate/0.15M NaCl/5% glycerol buffer on a 30 kDa NMWL membrane filter and then sterilized by passage

through a $\leq 0.22 \mu\text{m}$ membrane filter. This sterile bulk was stored at 2°C to 8°C and adsorption performed within three months.

The FHA fraction, prepared in pure form as described in Example 2, was toxoided by adjusting the L-lysine and formaldehyde concentration to $47 \pm 5\text{mM}$ and $0.24 \pm 0.05\%$ respectively and incubating at 35°C to 38°C for 6 weeks. The mixture was then diafiltered against 10mM potassium phosphate/ 0.5M NaCl using a 30 kDa NMWL membrane filter and sterilized by passage through a membrane filter. This sterile bulk was stored at 2°C to 8°C and adsorption performed within three months.

Example 4:

This Example describes the adsorption of the purified *Bordetella pertussis* antigens.

For the individual adsorption of PT, FHA, Agg and 69 kDa onto aluminum phosphate (alum), a stock solution of aluminum phosphate was prepared to a concentration of $18.75 \pm 1 \text{ mg/ml}$. A suitable vessel was prepared and any one of the antigens aseptically dispensed into the vessel. 2-phenoxyethanol was aseptically added to yield a final concentration of $0.6\% \pm 0.1\% \text{ v/v}$ and stirred until homogeneous. The appropriate volume of aluminum phosphate was aseptically added into the vessel. An appropriate volume of sterile distilled water was added to bring the final concentration to 3 mg aluminum phosphate/ml. Containers were sealed and labelled and allowed to stir at room temperature for 4 days. The vessel was then stored awaiting final formulation.

Example 5:

This Example describes the formulation of a component pertussis vaccine combined with diphtheria and tetanus toxoids.

The *B. pertussis* antigens prepared as described in the preceding Examples were formulated with diphtheria

and tetanus toxoids to provide several component pertussis (CP) vaccines.

The pertussis components were produced from *Bordetella pertussis* grown in submerged culture as described in detail in Examples 1 to 4 above. After completion of growth, the culture broth and the bacterial cells were separated by centrifugation. Each antigen was purified individually. Pertussis toxin (PT) and Filamentous Haemagglutinin (FHA) were purified from the broth by sequential chromatography over perlite and hydroxylapatite. PT was detoxified with glutaraldehyde and any residual PT (approximately 1%) present in the FHA fraction was detoxified with formaldehyde. Fimbrial Agglutinogens (2+3) (AGG) were prepared from the bacterial cells. The cells were disrupted with urea and heat treated, and the fimbrial agglutinogens were purified by precipitation with polyethylene glycol and chromatography over polyethyleneimine silica. The 69 kDa protein (pertactin) component was isolated from the run through from the perlite chromatography step (Example 2) by ammonium sulphate precipitation, and purified by sequential chromatography over hydroxylapatite and Q-sepharose. All components were sterilized by filtration through a 0.22 μ m membrane filter.

Diphtheria toxoid was prepared from *Corynebacterium diphtheriae* grown in submerged culture by standard methods. The production of Diphtheria Toxoid is divided into five stages, namely maintenance of the working seed, growth of *Corynebacterium diphtheriae*, harvest of Diphtheria Toxin, detoxification of Diphtheria Toxin and concentration of Diphtheria Toxoid.

Preparation of Diphtheria Toxoid

(I) Working Seed

The strain of *Corynebacterium diphtheriae* was maintained as a freeze-dried seed lot. The reconstituted seed was grown on Loeffler slopes for 18 to 24 hours at

35°C ± 2°C, and then transferred to flasks of diphtheria medium. The culture was then tested for purity and Lf content. The remaining seed was used to inoculate a fermenter.

5 **(II) Growth of *Corynebacterium diphtheriae***

The culture was incubated at 35°C ± 2°C and agitated in the fermenter. Predetermined amounts of ferrous sulphate, calcium chloride and phosphate solutions were added to the culture. The actual amounts of each
10 solution (phosphate, ferrous sulphate, calcium chloride) were determined experimentally for each lot of medium. The levels chosen are those which gave the highest Lf content. At the end of the growth cycle (30 to 50 hours), the cultures were sampled for purity, and Lf
15 content.

The pH was adjusted with sodium bicarbonate, and the culture inactivated with 0.4% toluene for 1 hour at a maintained temperature of 35°C ± 2°C. A sterility test was then performed to confirm the absence of live *C. diphtheriae*.
20

(III) Harvest of Diphtheria Toxin

The toluene treated cultures from one or several fermenters were pooled into a large tank. Approximately 0.12% sodium bicarbonate, 0.25% charcoal, and 23%
25 ammonium sulphate were added, and the pH was tested.

The mixture was stirred for about 30 minutes. Diatomaceous earth was added and the mixture pumped into a depth filter. The filtrate was recirculated until clear, then collected, and sampled for Lf content
30 testing. Additional ammonium sulphate was added to the filtrate to give a concentration of 40%. Diatomaceous earth was also added. This mixture was held for 3 to 4 days at 2°C to 8°C to allow the precipitate to settle. Precipitated toxin was collected and dissolved in 0.9%
35 saline. The diatomaceous earth was removed by filtration and the toxin dialysed against 0.9% saline, to remove the

ammonium sulphate. Dialysed toxin was pooled and sampled for Lf content and purity testing.

(IV) Detoxification of Diphtheria Toxin

Detoxification takes place immediately following dialysis. For detoxification, the toxin was diluted so that the final solution contained:

- a) diphtheria toxin at $1000 \pm 10\%$ Lf/ml.
- b) 0.5% sodium bicarbonate
- c) 0.5% formalin
- 10 d) 0.9% w/v L-lysine monohydrochloride

The solution was brought up to volume with saline and the pH adjusted to 7.6 ± 0.1 .

Toxoid was filtered through cellulose diatomaceous earth filter pads and/or a membrane prefilter and 0.2 μ m membrane filter into the collection vessel and incubated for 5 to 7 weeks at 34°C. A sample was withdrawn for toxicity testing.

(V) Concentration of Purified Toxoid

The toxoids were pooled, then concentrated by ultrafiltration, and collected into a suitable container. Samples were taken for Lf content and purity testing. The preservative (2-phenoxyethanol) was added to give a final concentration of 0.375 % and the pH adjusted to 6.6 to 7.6.

The toxoid was sterilized by filtration through a prefilter and a 0.2 μ m membrane filter (or equivalent) and collected. The sterile toxoid was then sampled for irreversibility of toxoid Lf content, preservative content, purity (nitrogen content), sterility and toxicity testing. The sterile concentrated toxoid was stored at 2°C to 8°C until final formulation.

Preparation of Tetanus Toxoid

Tetanus toxoid (T) was prepared from *Clostridium tetani* grown in submerged culture.

The production of Tetanus Toxoid can be divided into five stages, namely maintenance of the working seed,

growth of *Clostridium tetani*, harvest of Tetanus Toxin, detoxification of Tetanus Toxin and purification of Tetanus Toxoid.

(I) Working Seed

5 The strain of *Clostridium tetani* used in the production of tetanus toxin for the conversion to tetanus toxoid was maintained in the lyophilized form in a seed-lot. The seed was inoculated into thioglycollate medium and allowed to grow for approximately 24 hours at 35°C ±
10 2°C. A sample was taken for culture purity testing.

(II) Growth of *Clostridium tetani*

 The tetanus medium was dispensed into a fermenter, heat-treated and cooled. The fermenter was then seeded and the culture allowed to grow for 4 to 9 days at 34°C
15 ± 2°C. A sample was taken for culture purity, and Lf content testing.

(III) Harvest of Tetanus Toxin

 The toxin was separated by filtration through cellulose diatomaceous earth pads, and the clarified
20 toxin then filter-sterilized using membrane filters. Samples were taken for Lf content and sterility testing. The toxin was concentrated by ultrafiltration, using a pore size of 30,000 daltons.

(IV) Detoxification of Tetanus Toxin

25 The toxin was sampled for Lf content testing prior to detoxification. The concentrated toxin (475 to 525 Lf/ml) was detoxified by the addition of 0.5% w/v sodium bicarbonate, 0.3% v/v formalin and 0.9% w/v L-lysine monohydrochloride and brought up to volume with saline.
30 The pH was adjusted to 7.5 ± 0.1 and the mixture incubated at 37°C for 20 to 30 days. Samples were taken for sterility and toxicity testing.

(V) Purification of Toxoid

 The concentrated toxoid was sterilized through pre-
35 filters, followed by 0.2 µm membrane filters. Samples were taken for sterility and Lf content testing.

The optimum concentration of ammonium sulphate was based on a fractionation "S" curve determined from samples of the toxoid. The first concentration was added to the toxoid (diluted to 1900-2100 Lf/ml). The mixture
 5 was kept for at least 1 hour at 20°C to 25°C and the supernatant collected and the precipitate containing the high molecular weight fraction, discarded.

A second concentration of ammonium sulphate was added to the supernatant for the second fractionation to
 10 remove the low molecular weight impurities. The mixture was kept for at least 2 hours at 20°C to 25°C and then could be held at 2°C to 8°C for a maximum of three days. The precipitate, which represents the purified toxoid, was collected by centrifugation and filtration.

15 Ammonium sulphate was removed from the purified toxoid by diafiltration, using Amicon (or equivalent) ultrafiltration membranes with PBS until no more ammonium sulphate could be detected in the toxoid solution. The pH was adjusted to 6.6. to 7.6, and 2-phenoxyethanol
 20 added to give a final concentration of 0.375%. The toxoid was sterilized by membrane filtration, and samples are taken for testing (irreversibility of toxoid, Lf content, pH, preservative content, purity, sterility and toxicity).

25 One formulation of a component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{10/5/5/3}DT. Each 0.5 ml human dose of CP_{10/5/5/3}DT was formulated to contain:

30	10 µg	Pertussis toxoid (PT)
	5 µg	Filamentous haemagglutinin (FHA)
	5 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	3 µg	69 kDa outer membrane protein
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
35	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol as preservative

Another formulation of component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{10/5/5}DT. Each 0.5 ml human dose of CP_{10/5/5}DT was formulated to contain:

5	10 µg	Pertussis toxoid (PT)
	5 µg	Filamentous haemagglutinin (FHA)
	5 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
10	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol as preservative

Another formulation of Component Pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{20/20/5/3}DT. Each 0.5 ml human dose of CP_{20/20/5/3}DT was

15	formulated to contain:	
	20 µg	Pertussis toxoid (PT)
	20 µg	Filamentous haemagglutinin (FHA)
	5 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	3 µg	69 kDa outer membrane protein
20	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
	1.5 mg	Aluminum phosphate
	0.6%	2-phenoxyethanol as preservative

A further formulation of a component pertussis vaccine combined with diphtheria and tetanus toxoids was termed CP_{20/10/10/6}DT. Each 0.5 ml human dose of CP_{20/10/10/6}DT was formulated to contain:

30	20 µg	Pertussis toxoid (PT)
	10 µg	Filamentous haemagglutinin (FHA)
	10 µg	Fimbrial agglutinogens 2 and 3 (FIMB)
	6 µg	69 kDa outer membrane protein
	15 Lf	Diphtheria toxoid
	5 Lf	Tetanus toxoid
	1.5 mg	Aluminum phosphate
35	0.6%	2-phenoxyethanol as preservative

Example 6:

This Example describes the clinical assessment of Component Acellular Pertussis vaccines, produced in accordance with the invention.

5 **(a) Studies in Adults**

Studies in adults and children aged 16 to 20 months indicated the multi-component vaccines containing fimbrial agglutinogens to be safe and immunogenic (Table 2).

10 A Phase I clinical study was performed in 17 and 18 month old children in Calgary, Alberta with the five Component Pertussis vaccine (CP_{10/5/5/3}DT) and the adverse reaction reported. Thirty-three children received the vaccine and additionally 35 received the same vaccine
15 without the 69 kDa protein component.

Local reactions were rare. Systemic adverse reactions, primarily consisting of irritability were present in approximately half of study participants, regardless of which vaccine was given. Significant
20 antibody rises were measured for anti-PT, anti-FHA, anti-fimbrial agglutinogens and anti-69kDa IgG antibodies by enzyme immunoassay and anti-PT antibodies in the CHO cell neutralization test. No differences in antibody response were detected in children who received the four
25 component (CP_{10/5/5}DT) or five component (CP_{10/5/5/3}DT) except in the anti-69kDa antibody. Children who received the five component vaccine containing the 69 kDa protein had a significantly higher post-immunization anti-69 kDa antibody level.

30 A dose-response study was undertaken with the 4 component vaccine in Winnipeg, Manitoba, Canada. Two component vaccine formulations were used: CP_{10/5/5/3}DT and CP_{20/10/10/6}DT. A whole-cell DPT vaccine was also included as a control.

35 This study was a double-blind study in 91, 17 to 18 month old infants at the time of their booster pertussis

dose. Both CP_{10/5/5/3}DT and CP_{20/10/10/6}DT were well tolerated by these children. No differences were demonstrated in the number of children who had any local reaction, or systemic reactions after either of the component
5 vaccines. In contrast, significantly more children who received the whole-cell vaccine had local and systemic reactions than those who received the CP_{20/10/10/6}DT component vaccines.

Studies in Infants:

10 Phase II:

A study was conducted using the CP_{10/5/5/3}DT vaccine in Calgary, Alberta and British Columbia, Canada. In this study, 432 infants received the component pertussis vaccine or the whole-cell control vaccine DPT at 2, 4 and
15 6 months of age. The CP_{10/5/5/3}DT vaccine was well tolerated by these infants. Local reactions were less common with the component vaccine than the whole cell vaccine after each dose.

A significant antibody response to all antigens was
20 demonstrated after vaccination with the component pertussis vaccine. Recipients of the whole-cell vaccine had a vigorous antibody response to fimbrial agglutinogens, D and T. At seven months, 82% to 89% of component vaccine recipients and 92% of whole cell
25 vaccine recipients had a four-fold increase or greater rise in antibody titer to fimbrial agglutinogens. In contrast, antibody response to FHA was 75% to 78% in component vaccines compared to 31% of whole-cell recipients. A four-fold increase in anti-69 kDa antibody
30 was seen in 90% to 93% of component vaccines and 75% of whole-cell recipients. A four-fold rise in antibody against PT by enzyme immunoassay was seen in 40% to 49% of component vaccines and 32% of whole-cell vaccines; a four-fold rise in PT antibody by CHO neutralization was
35 found in 55% to 69% of component and 6% of whole-cell vaccines. (Table 2).

Phase IIB:

The CP_{20/20/5/3}DT and CP_{10/10/5/3}DT vaccines were assessed in a randomized blinded study against a D₁₅PT control with a lower diphtheria content of 15 Lf compared to a 25 Lf formulation of 100 infants at 2, 4 and 6 months of age. No differences in rates of adverse reactions were detected between the two components formulations; both were significantly less reactogenic than the whole-cell control. Higher antibody titers against PT by enzyme immunoassay and CHO neutralization and FHA were achieved in recipients of the CP_{20/20/5/3}DT vaccine with increased antigen content. At 7 months, the anti-FHA geometric mean titer was 95.0 in CP_{20/20/5/3}DT recipients, 45.2 in CP_{10/5/5/3}DT recipients were only 8.9 in D₁₅PT recipients. Anti-PT titers were 133.3, 58.4 and 10.4 by immunoassay and 82.4, 32.7 and 4.0 by CHO neutralization respectively (Table 2).

This study demonstrated that the Component Pertussis vaccine combined with diphtheria and tetanus toxoids adsorbed, with increased antigen content, was safe and immunogenic in infants and that the increased antigen content augmented the immune response to the prepared antigens (PT and FHA) without an increase in reactogenicity.

25 NIAID, PHASE II, U.S. Comparative Trial:

A phase II study was performed in the United States under the auspices of the National Institute of Allergy and Infectious Diseases (NIAID) as a prelude to a large scale efficacy trial of acellular pertussis vaccines. One component pertussis vaccine of the invention in combination with diphtheria and tetanus toxoids adsorbed (CP_{10/5/5/3}DT) was included in that trial along with 12 other acellular vaccines and 2 whole-cell vaccines. Safety results were reported on 137 children immunized at 2, 4 and 6 months of age with the CP_{10/5/5/3}DT component vaccine.

As seen in previous studies, the component vaccine was found to be safe, of low reactogenicity and to be well tolerated by vaccines.

At 7 months, anti-PT antibody, anti-FHA antibody, anti-69kDa antibody and anti-fimbrial agglutinogens antibody were all higher than or equivalent to levels achieved after the whole-cell vaccines (ref 71 and Table 2). A double blind study was performed in which children were randomly allocated to receive either the CP_{20/20/5/3}DT or the CP_{10/5/5/3}DT vaccine formulation. A total of 2050 infants were enrolled in the United States and Canada; 1961 infants completed the study. Both vaccine formulations were safe, of low reactogenicity and immunogenic in these infants. Immunogenicity was assessed in a subgroup of 292. An antibody rise was elicited to all antigens contained in the vaccine by both vaccine formulations. The CP_{20/20/5/3}DT formulation induced higher antibody titers against FHA but not PT. The CP_{10/5/5/3}DT formulation elicited higher titers against fimbriae and higher agglutinin titers.

A further safety and immunogenicity study was conducted in France. The study design was similar to the North American study, described above, except that vaccines were administered at 2, 3 and 4 months of age. Local and systemic reactions were generally minor. Overall the vaccine was well accepted by the French study participants using this administration regime.

Placebo-controlled efficacy trial of two acellular pertussis vaccines and of a whole-cell vaccine in 10,000 infants

Following the results of the NIAID Phase II U.S. comparative trial, a two-component and a five-component acellular vaccine were selected for a multi-centre, controlled, double-randomized placebo-controlled efficacy trial. The clinical trial was performed in Sweden, where there is a high incidence of pertussis. The two-component vaccine contained glyceraldehyde and formalin

inactivated PT (25 μ g), formalin treated FHA (25 μ g) and diphtheria toxoid 17 Lf and tetanus toxoid 10 Lf. The five-component pertussis vaccine was CP_{10/5/5/3}DT. For the trial, ten thousand infants, representing approximately
5 one-half the infants of this age group in Sweden, were recruited in 14 geographically defined study sites by use of birth registry.

Children born in January and February 1992 were randomized into a 3-armed trial. After parental consent,
10 two-thirds of the infants received one out of the two diphtheria-tetanus-acellular pertussis preparations at two, four and six months of age. The control group received DT only. In May 1992, a U.S. Licensed commercially-available whole-cell DTP vaccine was
15 introduced and children born in March through December 1992 were randomized into a 4-armed trial. After parental consent, three-quarters of the infants received one out of three DTP preparations at two, four and six months of age. The control group received DT only.

20 Each vaccine was administered to about 2,500 children. Vaccines were administered in three doses. The first dose was given at 2 months of age and not later than 3 months of age. Subsequent doses were given with 8 week intervals. Vaccines were given by intramuscular
25 injection.

The children and their households were followed for 30 months. If pertussis was suspected, clinical data was collected, and laboratory verification sought by nasal aspirates for bacteriological culture and polymerase
30 chain reaction (PCR) diagnosis. Acute and convalescent blood samples were collected for serological diagnosis.

Prior to this study, the extent of pertactin afforded by component pertussis vaccines of the present invention in an at-risk human population (particularly
35 neonates) was unknown. In particular, the contribution of the various Bordetella components and their presence

in pertussis vaccines in selected relative amounts to efficacy of the vaccines was not known.

The main aim of the trial was to estimate the ability of acellular pertussis vaccines and whole-cell vaccine to protect against typical pertussis as compared to placebo.

A secondary end-point was to explore vaccine efficacy against confirmed pertussis infection of varying severity.

Vaccine efficacy is defined as the per cent reduction in the probability of contracting pertussis among vaccine recipients relative to unvaccinated children.

The relative risk of pertussis in two vaccine groups is expressed as the ratio of the disease probability in the two groups.

The probability of contracting pertussis, also called the attack rate, can be estimated in different ways. In the calculations of the sample size, the probability of contracting pertussis in a given study group is estimated by the quotient between the number of children with pertussis and the children remaining in the study group at the termination of study follow-up.

The efficacy of the component vaccine CP_{10/5/5/3}DT in this trial in preventing typical pertussis is shown in Table 4 and was about 85%. In the same trial, a two-component pertussis acellular vaccine containing only PT and FHA was about 58% efficacious and a whole-cell vaccine was about 48% efficacious. The CP_{10/5/5/3}DT was also effective in preventing mild pertussis at an estimated efficacy of about 77%.

SUMMARY OF DISCLOSURE

In summary of this disclosure, the present invention provides novel preparations of fimbrial agglutinogens of *Bordetella pertussis* and methods for their production. The fimbrial agglutinogens can be formulated with other

Bordetella and non-*Bordetella* antigens to produce a number of multi-component pertussis vaccines. Such vaccines are safe, non-reactogenic, immunogenic and protective in humans. Modifications are possible within
5 the scope of this invention.

Table 1. Acellular Pertussis Vaccines

Vaccine	PT	Toxoiding Agent	FHA	P.69	AGG2	AGG3	Reference
AMVC	+	H ₂ O ₂ ^a	-	-	-	-	62
Mass PHL ^b	+	TMN ^c	-	-	-	-	63
Institut Mérieux	+	GI ^d	+	-	-	-	64
Smith-Kline	+	FI ^e /GI	+	-	-	-	32
	+	FI/GI	+	+	-	-	32
CAMR ^f	+	FI	+	-	+	+	65
Lederle/Takeda	+	FI	+	+	+	-	66
Connaught	+	GI	+	-	+	+	32
	+	GI	+	+	+	+	67

^a Hydrogen peroxide inactivated. ^b Massachusetts Public Health Laboratories. ^c TNM, tetranitromethane-inactivated.

^d GI, glutaraldehyde-inactivated. ^e FI, formalin-inactivated. ^f Centre for Applied Microbiology and Research.

Table 2.
IgG antibody responses to pertussis antigen and diphtheria and tetanus toxoids in adults and young children after immunization with placebo or acellular pertussis (AP), diphtheria-tetanus-pertussis (DTP), or multicomponent acellular DTP (ADTP) toxoids.

	Adults				Children			
	Before immunization		Postimmunization day 28		Before immunization		After immunization	
	Placebo	AP CP _{103/5/3}	Placebo	AP CP _{103/5/3}	DTP	ADTP CP _{1010/5/3} DT	DTP	ADTP CP _{1010/5/3} DT
Pertussis toxoid	16.45 (9.46-28.62)	22.78 (12.11-42.86)	16.36 (9.08-30.22)	415.87 (243.91-709.09)	43.71 (14.29-133.88)	15.45 (8.50-28.10)	221.32 (99.83-490.67)	306.55 (155.84-603.03)
Filamentous hemagglutinin	15.24 (10.26-22.60)	23.59 (15.59-35.69)	13.36 (7.71-23.16)	317.37 (243.05-141.41)	2.93 (1.81-4.73)	3.86 (3.03-4.93)	30.06 (11.82-76.46)	29.86 (16.51-53.99)
Agglutinogens	21.26 (12.14-37.23)	28.64 (12.20-67.21)	27.0 (15.37-47.78)	2048.00 (1025.62-4089.55)	26.72 (16.94-42.15)	29.24 (13.63-62.75)	315.2 (127.4-779.9)	1243.3 (594.8-2603.5)
Pertactin	7.89 (4.00-15.56)	11.47 (6.41-20.55)	7.46 (3.51-15.87)	855.13 (396.41-1844.67)	6.54 (2.79-15.33)	9.43 (5.50-16.23)	60.13 (24.59-147.04)	116.16 (57.87-233.19)
CHIO cell neutralizing assay	12.30 (6.97-21.68)	21.11 (10.35-43.06)	10.78 (5.54-20.97)	604.67 (403.82-405.41)	27.47 (7.36-102.62)	9.71 (4.71-20.03)	270.60 (24.6-1100.8)	342.51 (146.6-800.2)
Diphtheria toxoid	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	8.75 (6.32-23.92)	9.65 (5.62-16.57)
Tetanus toxoid	<0.1	<0.1	<0.1	<0.1	<0.1	<0.1	4.11 (3.20-5.28)	6.32 (5.31-7.53)
No. studied	16	15	16	15	10	25	12	25

Data are expressed as geometric mean with 95% confidence intervals. For pertussis toxoid, filamentous hemagglutinin, agglutinogens, pertactin, and diphtheria and tetanus toxoids, antibody titers expressed as ELISA units/nL. For CHIO cell neutralizing assay, values reflect reciprocal of highest dilution demonstrating 80% neutralization.

TABLE 3. Serologic Results of Acellular Pertussis Vaccines In Infants
(2, 4 and 6 Months Old)

Clinical Trial	Geometric Mean Titres										
	Product	Study	Number of Participants	PT	FHA	69 kDa	Fimbrial agglutinogens	CHO Cell Neutralization	Agglutination	Tet	Dip
1	CP _{105/53} DT	U.S. NIAID Multicentre Comparative Study (Cycle I)	108	38	37	3	229	160	85	7.8	0.8
	CP _{105/53} DT Whole Cell (Mass.) Whole Cell (Lederle)		113 95 312	36 20 67	36 51 3	113 101 64	241 70 193	150 80 270	73 42 84	5.0 - -	0.4 - -
2	CP _{105/53} DT Whole Cell (CLL)	Phase II Canada	315 101	87.1 20	50.2 4.7	29.9 6.4	239.8 603.2	29.6 2.6	- -	1.5 1.2	0.3 0.4
	CP _{105/53} DT CP _{202/53} DT Whole Cell (CLL)		32 33 30	58.4 133.3 10.4	45.2 95.0 8.9	40.6 37.1 6.8	111.4 203.8 393.9	32.7 82.4 4.0	- - -	1.0 1.1 1.8	0.14 0.21 0.31
4	CP _{105/53} DT CP _{202/53} DT	Phase IIC Canada	42 250	105.1 101.6	82.5 163.9	71.1 87.6	358.6 220.6	66.9 68.7	307.0 219.2	2.0 1.8	0.33 0.38
	CP _{202/53} DT Whole Cell (CLL)		58 58	212.7 101.4	83.4 11.7	106.3 16.8	601.9 906.9	109.6 6.0	- -	1.9 1.1	0.53 0.27
6	CP _{105/53} DT CP _{202/53} DT Whole Cell (CLL)	U.S. NIAID Comparative Study (Cycle II)	80 80 80 80	42 39 2 18	34 87 3 2	50 43 9 16	310 184 33 129	196 254 54 137	185 137 167 86	- -	- -

CLJ - Connaught Laboratories Incorporated, Swiftwater, Pennsylvania.

CLL - Connaught Laboratories Limited, Willowdale, Ontario.

Mass - Massachusetts Public Laboratories.
Lederle - Lederle Laboratories Inc.

TABLE 4 - Efficacy of Acellular Pertussis Vaccines

	<u>Vaccine</u>	<u>Efficacy %</u>	
		<u>A</u>	<u>B</u>
5	CP _{10/5/5/3} DT	84.7 (80.3→88.5) ¹	77
	PT ₂₅ .FHA ₂₅ DT	58 (49.8→64.8) ¹	
	DPT ²	47.9 (37.1→56.9) ¹	
10	A: case definition:	21 day spasmodic cough and culture positive	
	B: case definition:	mild pertussis cough of at least one day	
	Note 1: confidence limits		
15	Note 2: whole cell pertussis vaccine		

REFERENCES

1. Muller, A.S. Leeuwenburg, J. and Pratt, D.S. (1986) Pertussis: epidemiology and control. *Bull WHO* 64: 321-331.
2. Fine, P.E.M. and Clarkson, J.A. (1984). Distribution of immunity to pertussis in the population of England and Wales. *J. Hyg.* 92:21-26.
3. Mortimer, E.A. Jr. (1990). Pertussis and its prevention: a family affair. *J. Infect. Dis.* 161: 473-479.
4. Addiss, D.G., Davis, I.P., Meade, B.D., Burstyn, D.G. Meissner, M., Zastrow, J.A., Berg, J.L., Drinka, P., and Phillips, R. (1991). A pertussis outbreak in a Wisconsin nursing home. *J. Infect. Dis.* 164: 704-710.
5. Halperin, S.A. and Marrie, T.J. (1991a). Pertussis encephalopathy in an adult: case report and review. *Rev. Infect. Dis.* 13: 1043-1047.
6. Onorato, I.M., Wassilak, S.G. and Meade, B. (1992). Efficacy of whole-cell pertussis vaccine in preschool children in the United States. *JAMA* 267: 2745-2749.
7. Miller, D.L., Ross, E.M., Alderslade, R., Bellman, M.H., and Brawson, N.S.B. (1981). Pertussis immunization and serious acute neurological illness in children. *Brit Med. J.* 282: 1595-1599.
8. Tamura, M., Nogimori, K., Murai, S., Yajima, M., Ito, K., Katada, T., Ui, M., and Ishii, S. (1982). Subunit structure of islet-activating protein. pertussis toxin, in conformity with the A-B model. *Biochemistry* 21: 5516-5522.
9. Tuomanen, E. and Weiss, A. (1985). Characterization of two adhesins of *Bordetella pertussis* for human ciliated respiratory epithelial cells. *J. Infect. Dis.* 152:118-125.
10. Friedman, R-L., Nordensson, K., Wilson, L., Akporiaye, E.T., and Yocum D.E. (1992). Uptake and intracellular survival of *Bordetella pertussis* in human macrophages. *Infect. Immun.* 60: 4578-4585
11. Pittman, M (1979). Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. *Rev. Infect. Dis.*, 1: 401-402

12. Granstrom, M. and Granstrom G. (1993). Serological correlates in whooping cough. *Vaccine* 11:445-448.
13. Gearing, A.J.H., Bird, C.R., Redhead, K., and Thomas, M. (1989). Human cellular immune responses to *Bordetella pertussis* infection. *FEMS Microbial. Immunol.* 47: 205-212.
14. Thomas, M.G., Redhead, K., and Lambert, H.P. (1989a). Human serum antibody responses to *Bordetella pertussis* infection and pertussis vaccination. *J. Infect. Dis.* 159: 211-218.
15. Thomas, M.G., Ashworth, L.A.E., Miller, E., and Lambert, H.P. (1989b). Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous haemagglutinin, and agglutinogens 2 and 3 after infection with *Bordetella pertussis* and immunization with whole-cell pertussis vaccine. *J. Infect. Dis.* 160: 838-845.
16. Tomoda, T., Ogura, H., and Kurashige, T. (1991). Immune responses to *Bordetella pertussis* infection and vaccination. *J. Infect. Dis.* 163: 559-563.
17. Petersen, J.W., Ibsen, P.H., Haslov, K., Capiou, C., and Heron, I. (1992a). Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from trachobroncheal lymph nodes and spleens of mice aerosol infected with *Bordetella pertussis*. *Infect. Immun.* 60: 4563-4570
18. Englund, J.A., Reed, G.F., Edwards, K.M., Decker, D., Pichichero, M.E., Ronnels, M.B., Steinhoff, M.C., Anderson, E.L., Meade, B.D., Deloria, M.A., and the NIAID Acellular Pertussis Vaccine Group. (1992b). Effect of transplacental antibody and development of pertussis toxin (PT) and filamentous haemagglutinin (FHA) antibody after acellular (AC) and whole cell (WC) pertussis vaccines in infants. *Pediat. Res.* 31:91A.
19. Oda, M., Cowell, J.L., Burstyn, D.G., Thaib, S., and Manclark, C.R. (1985). Antibodies to *Bordetella pertussis* in human colostrum and their protective activity against aerosol infection of mice. *Infect. Immun.* 47:441-445.
20. Petersen, J.W., P.H. Bentzon, M.W., Capiou, C., and Heron, I. (1991). The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans. *FEMS Microbiol Lett.* 76: 279-288.

21. Oda, M., Cowell, J.L., Burstyn, D.G., and Manclark, C.R. (1984). Protective activities of the filamentous haemagglutinin and the lymphocytosis-promoting factor of *Bordetella pertussis* in mice. *J. Infect. Dis.* 150: 823-833.
22. Sato, H., Ito, A., Chiba, J. and Sato, Y. (1984b). Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. *Infect. Immun.* 46: 422-428.
23. Sato, H. and Sato, Y. (1990). Protective activities in mice of monoclonal antibodies against pertussis toxin. *Infect. Immun.* 58: 3369-3374.
24. Weiss, A.A. and Hewlett, E.L. (1986). Virulence factors of *Bordetella pertussis*. *Ann. Rev. Microbiol.* 40: 661-668.
25. Munoz, J.J. (1988). Action of pertussigen (pertussis toxin) on the host immune system. In: *Pathogenesis and Immunity in Pertussis*. A.C. Wardlaw and R. Parton, eds., John Wiley & Sons Ltd., Toronto. pp. 211-229.
26. Watkins, P.A., Burns, D.L., Kanaho, Y., Liu, T-Y., Hewlett E.L., and Moss, J. (1985). ADP-ribosylation of transducin by pertussis toxin. *J. Biol. Chem.* 260: 13478-13482.
27. Burns, D.L., Kenimer, J.G., and Manclark, C.R. (1987). Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. *Infect. Immun.*, 55: 24-28.
28. Munoz, J.J., Arai, H., and Cole, R.L. (1981). Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinins from *Bordetella pertussis*. *Infect. Immun.* 32: 243-250.
29. Relman, D.A., Domenighini, M., Tuomanen, E., Rappuoli, R., and Falkow, S. (1989). Filamentous haemagglutinin of *Bordetella pertussis*: nucleotide sequence and crucial role in adherence. *Proc. Natl. Acad. Sci. USA* 86: 2637-2641.
30. Di Tommaso, A., Domenighini, M., Bugnoli, M., Tagliabuc, A., Rappuoli, R., and De Magistris, M.T. (1991). Identification of subregions of *Bordetella pertussis* filamentous haemagglutinin that stimulate human T-cell responses. *Infect. Immun.* 59: 3313-3315.

31. Tomoda, T., Ogura, H., and Kurashige, T. (1992). The longevity of the immune response to filamentous haemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community. *J. Infect. Dis.* 166: 908-910.
32. Edwards, K.M., Meade, B.D., Decker, M.D., Reed, G.F., Rennels, M.B., Steinhoff, M.C., Anderson, E.L., Englund, J.A., Pichichero, M.E., Deloria, M.A., Deforest, A., and the NIAID Acellular Pertussis Vaccine Study Group (1992). Comparison of thirteen acellular pertussis vaccines: serological response. *Pediatr. Res.* 31:91A.
33. Kimura, A., Mountzoutos, K.T., Relman, D.A., Falkow, S., and Cowell, J.L. (1990a). *Bordetella pertussis* filamentous haemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. *Infect. Immun.* 58:7-16.
34. Shahin, R.D., Amsbaugh, D.F., and Leef, M.F. (1992). Mucosal immunization with filamentous haemagglutinin protects against *Bordetella pertussis* respiratory infection. *Infect. Immun.* 60: 1482-1488.
35. Montaraz, J.A., Novotny, P., and Ivanyi, J. (1985). Identification of a 68-kilodalton protective protein antigen from *Bordetella bronchiseptica*. *Infect. Immun.* 161: 581-582.
36. Leininger, E., Roberts, M., Kenimer, J.G., Charles, I.G., Fairweather, M., Novotny, P., and Brennan, M.J. (1991). Pertactin, and Arg-Gly-Asp-containing *Bordetella pertussis* surface protein that promotes adherence of mammalian cells. *Proc. Natl. Acad. Sci. USA* 88: 345-349.
37. De Magistris, T., Romano, M., Nuti, S., Rappuoli, R., and Tagliabue, A. (1988). Dissecting human T responses against *Bordetella* species. *J. Exp. Med.* 168: 1351-1362.
38. Seddon, P.C., Novotny, P., Hall, C.A., and Smith, C.S. (1990). Systemic and mucosal antibody response to *Bordetella pertussis* antigens in children with whooping cough. *Serodiagnosis Immunother. Inf. Dis.* 3: 337-343.
39. Podda, A., Nencioni, L., Marsili, I., Peppoloni, S., Volpini, G., Donati, D., Di Tommaso, A., De Magistris, M.T., and Rappuoli, R. (1991). Phase I clinical trial of an acellular pertussis vaccine

composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9: 741-745.

40. Roberts, M., Tite, J.P., Fairweather, N.F., Dougan, G. and Charles, I.G. (1992). Recombinant P.69/pertactin: immunogenicity and protection of mice against *Bordetella pertussis* infection. Vaccine 10: 43-48.
41. Novotny, P., Chubb, A.P., Cownley, K., and Charles, I.G. (1991). Biological and protective properties of the 69kDa outer membrane protein of *Bordetella pertussis*: a novel formulation for an acellular vaccine. J. Infect. Dis. 164: 114-122.
42. Shahin, R. D., Brennan, M.J., Li. Z.M., Meade, B.D., and Manclark, C.R. (1990b). Characterization of the protective capacity and immunogenicity of the 69kD outer membrane protein of *Bordetella pertussis*. J. Exp. Med. 171: 63-73.
43. Robinson, A., Irons, L.I., and Ashworth, L.A.E. (1985a). Pertussis vaccine: present status and future prospects. Vaccine 3: 11-22.
44. Robinson, A., Ashworth, L.A.E. Baskerville, A., and Irons, L.I. (1985b). Protection against intranasal infection of mice with *Bordetella pertussis*. Develop. Biol. Stand. 61: 165-172
45. Robinson, A., Gorringe, A.R., Funnell, S.G.P., and Fernandez, M. (1989b). Serospecific protection of mice against in infection with *Bordetella pertussis*. Vaccine 7: 321-324.
46. Sato, Y., Kimura, M., and Fukumi, H. (1984a). Development of a pertussis component vaccine in Japan. Lancet i: 122-126.
47. Kimura, M. (1991). Japanese clinical experiences with acellular pertussis vaccines. Develop. Biol. Standard. 73: 5-9.
48. Ad Hoc Group for the Study of Pertussis Vaccines (1988). Placebo-controlled trial of two acellular vaccines in Sweden-protective efficacy and adverse effects. Lancet i :955-960.
49. Olin, P., Storsaeter, J., and Romanus, V. (1989). The efficacy of acellular pertussis vaccine. JAMA 261:560.
50. Storsaeter, J., Hallander, H., Farrington, C.P., Olin, P., Moliby, R., and Miller, E. (1990).

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. *Vaccine* 8: 457-462.

51. Storsaeter, J., and Olin, P. (1992). Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. *Vaccine*: 10: 142-144.
52. Tan, L.U.T., Fahim R.E.F., Jackson, G., Phillips, K., Wah, P., Alkema, D., Zobrist, G., Herbert, A., Boux, L., Chong, P., Harjee, N., Klein, M., and Vose, J. (1991). A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous haemagglutinin. *Molec. Immunol.* 28: 251-255.
53. Sekura, R.D., Zhang, Y., Roberson, R., Acton, B., Trollfors, B., Tolson, N., Siloach, J., Bryla, D., Muir-Nash, J., Koeller, D., Schneerson, R., and Robbins, J.B. (1988). Clinical, metabolic, and antibody responses of adult volunteers to an investigation vaccine composed of pertussis toxin inactivated by hydrogen peroxide. *J. Pediatr.* 113: 807-813.
54. Winberry, L., Walker, R., Cohen, N., Todd, C., Sentissi, A., and Siber, G. (1988), Evaluation of a new method for inactivating pertussis toxin with tetranitromethane. *International Workshop on Bordetella pertussis*, Rocky Mountain Laboratories, Hamilton, Montana.
55. Sekura, R.D. et al. (1993), *J.Biol. Chem.* 258: 14647-14651.
56. Irons, L.I. et al. (1979), *Biochem. Biophys. Acta* 580: 175-185.
57. Munoz, J.J. et al. (1981). *Infect. Immun.* 33: 820-826.
58. Cowell, J.L. et al. (1980), *Seminar on Infectious Diseases* 4: 371-379.
59. Selmer, J.C. (1984) *Acta Path. Microbial. Immunol. Scand. Sect. C*, 92: 279-284.
60. Lockhoff, O. (1991) Glycolipids as Immunomodulators: Synthesis and Properties, *Chem. Int. Ed. Engl.* 30: 1611-1620.
61. Nixon-George, A., Moran, T., Dionne, G., Penney, C.L., Lafleur, D., Bona, C.A. (1990) The adjuvant

effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. *J. Immunol.* 144: 4798-4802.

62. Siber, G.R., Thakrar, N., Yancey, B.A., Herzog, L., Todd, C., Cohen, N., Sekura, R.D., Lowe, C.U. (1991). Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. *Vaccine* 9: 735-740.
63. Siber, G., Winberry, L., Todd, C., Samore, M., Sentissi, A., and Cohen, N. (1988). Safety and immunogenicity in adults of pertussis toxoid inactivated with tetranitromethane. In: *International Workshop on Bordetella pertussis*, Rocky Mountain Laboratories, Hamilton, Montana.
64. Edwards, K.M., Bradley, R.B., Decker, M.D., Palmer, P.S., Van Savage, J., Taylor, J.C., Dupont, W.D., Hager, C.C., and Wright, P.F. (1989). Evaluation of a new highly purified pertussis vaccine in infants and children. *J. Infect. Dis.* 160: 832-837.
65. Rutter, D.A., Ashworth, L.A.E., Day, A., Funnell, S., Lovell, F., and Robinson, A. (1988). Trial of new acellular pertussis vaccine in healthy adult volunteers. *Vaccine* 6: 29-32.
66. Blumberg, D.A., Mink, C.A.M., Cherry, J.D., Johnson, C., Garber, R., Plotkin, S.A., Watson, B., Ballanco, G.A., Daum, R.S., Sullivan, B., Townsend, T.R., Brayton, J., Gooch, W.M., Nelson, D.B., Congeni, B.L., Prober, C.G., Hackell, J.G., Dekker, C.L., Christenson, P.D., and the APDT Vaccine Study Group (1991). Comparison of acellular and whole cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. *J. Pediatr.* 119: 194-204.
67. Englund, J.A., Glezen, W.P. and Barreto, L. (1992a). Controlled study of a new five-component acellular pertussis vaccine in adults in young children. *J. Inf. Dis.* 166: 1436-1441.
68. Zealey, G., Loosmore, S., Yacoob, R., Klein, M., *Vaccine Research*, Vol. 1, pp. 413-427.

CLAIMS

What we claim is:

1. A vaccine composition for protecting an at-risk human population against a case of disease caused by infection by B. pertussis, which comprises pertussis toxoid, filamentous haemagglutinin, pertactin and agglutinogens of B. pertussis in purified form in selected relative amounts to confer protection to the extent of at least about 70% of members of the at-risk population.
2. The vaccine of claim 1 wherein said pertussis toxoid is present in an amount of about 5 to about 30 μg nitrogen, said filamentous haemagglutinin is present in an amount of about 5 to about 30 μg nitrogen, said pertactin is present in an amount of about 3 to about 15 μg nitrogen and said agglutinogens are present in an amount of about 1 to about 10 μg nitrogen, in a single human dose.
3. The vaccine of claim 2 containing about 10 μg nitrogen of pertussis toxoid, about 5 μg nitrogen of filamentous haemagglutinin, about 5 μg nitrogen of pertactin and about 3 μg nitrogen of agglutinogens in a single human dose.
4. The vaccine of claim 2 containing about 20 μg nitrogen of pertussis toxoid, about 20 μg nitrogen of filamentous haemagglutinin, about 5 μg nitrogen of pertactin and about 3 μg nitrogen of agglutinogens in a single human dose.
5. The vaccine of claim 1 wherein the extent of protection is at least about 80% for a case of pertussis having a spasmodic cough of duration at least 21 days and confirmed bacterial infection.
6. The vaccine of claim 1 wherein the extent of protection is at least about 70% for a case of mild pertussis having a cough of at least one day duration.

7. The vaccine of claim 2 wherein the extent of protection is about 85% for a case having a spasmodic cough of duration at least 21 days and confirmed bacterial infection.

8. The vaccine of claim 1 wherein said agglutinin comprise fimbrial agglutinin 2 (Agg 2) and fimbrial agglutinin 3 (Agg 3) substantially free from agglutinin 1.

9. The vaccine of claim 8 wherein the weight ratio of Agg 2 to Agg 3 is from about 1.5:1 to about 2:1.

10. The vaccine of claim 1 further comprising tetanus toxoid and diphtheria toxoid.

11. The vaccine of claim 10 wherein said diphtheria toxoid is present in an amount of about 15 Lfs and tetanus toxoid is present in an amount of about 5 Lfs.

12. The vaccine of claim 1 further comprising an adjuvant.

13. The vaccine of claim 12 wherein the adjuvant is alum.


14. A method of immunizing an at-risk human population against disease caused by infection by B. pertussis, which comprises administering to members of the at-risk human population an immunoeffective amount of the vaccine composition of claim 1 to confer protection to the extent of at least about 70% of the members of the at-risk population.

15. Purified forms of pertussis toxin, filamentous haemagglutinin, pertactin and fimbrial agglutinogens of B. pertussis when used in the manufacture of a vaccine composition for administration to an at risk human population to confer protection to the extent of at least about 70% of members of said at risk human population.

16. The use of claim 15 wherein there is used in the manufacture of a single human dose of the vaccine composition, from about 5 to about 30 μ g of nitrogen of said pertussis toxoid, about 5 to about 30 μ g of nitrogen

of said filamentous haemogglutinin, about 3 to about 15 μg of nitrogen of pertactin and about 1 to about 10 μg of nitrogen of the fimbrial agglutinogens.

Figure 1



INTERNATIONAL SEARCH REPORT

International Application No

PC1/CA 96/00278

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K39/10 A61K39/116 //C07K14/235

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THE JOURNAL OF INFECTIOUS DISEASES, vol. 166, no. 6, December 1992, CHICAGO, US, pages 1436-1441, XP000578930 J.A. ENGLUND ET AL.: "CONTROLLED STUDY OF A NEW FIVE-COMPONENT ACELLULAR PERTUSSIS VACCINE IN ADULTS AND YOUNG CHILDREN." cited in the application see the whole document ---	1-16
X	THE JOURNAL OF MEDICAL MICROBIOLOGY, vol. 35, no. 3, September 1991, EDINBURGH, GB, page 187 XP002010693 J.R. VOSE: "A NEW ACELLULAR PERTUSSIS VACCINE." see page 187, left-hand column --- -/-	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 August 1996

Date of mailing of the international search report

20.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

International Application No

PC./CA 96/00278

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, 207TH ACS NATIONAL MEETING, MARCH 13-17, 1994, SAN DIEGO, CA, US, vol. 207, no. 1-2, 1994, WASHINGTON, DC, US, page BIOT 25 XP000578228 R. FAHIM ET AL.: "DEVELOPMENT OF A WHOOPING COUGH ACELLULAR VACCINE." see the entire abstract ---	1-16
X	EP,A,0 484 621 (AMERICAN CYANAMID COMPANY) 13 May 1992 see claims ---	1,5-7, 10-15
P,X	WO,A,95 29934 (TAKEDA CHEMICAL INDUSTRIES) 9 November 1995 see page 34, line 6 - line 17; claim 15; table 7 -----	1-7, 12-16

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA96/00278

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 14 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/CA 96/00278

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-484621	13-05-92	CA-A- 2046543	12-01-92
-----	-----	-----	-----
WO-A-9529934	09-11-95	AU-B- 2352595	29-11-95
		JP-A- 8009980	16-01-96
-----	-----	-----	-----